Literature DB >> 18378982

Longitudinal studies of cognition in schizophrenia: meta-analysis.

Andrei Szöke1, Anca Trandafir, Marie-Estelle Dupont, Alexandre Méary, Franck Schürhoff, Marion Leboyer.   

Abstract

BACKGROUND: A wide range of cognitive deficits have been demonstrated in schizophrenia, but their longitudinal course remains unclear. AIMS: To bring together all the available information from longitudinal studies of cognitive performance in people with schizophrenia.
METHOD: We carried out a meta-analysis of 53 studies. Unlike previous reviewers, we included all studies (regardless of the type of medication), analysed each variable separately and compared results with data from controls.
RESULTS: Participants with schizophrenia showed a significant improvement in most cognitive tasks. The available data for controls showed, with one exception (the Stroop test), a similar or greater improvement. Performance in semantic verbal fluency remained stable in both individuals with schizophrenia and controls.
CONCLUSIONS: Participants with schizophrenia displayed improvement in most cognitive tasks, but practice was more likely than cognitive remediation to account for most of the improvements observed. Semantic verbal fluency may be the best candidate cognitive endophenotype.

Entities:  

Mesh:

Year:  2008        PMID: 18378982     DOI: 10.1192/bjp.bp.106.029009

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  74 in total

1.  The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia.

Authors:  Eri Nakagami; Maanse Hoe; John S Brekke
Journal:  Schizophr Bull       Date:  2010-05-12       Impact factor: 9.306

Review 2.  Vocational, social, and cognitive rehabilitation for individuals diagnosed with schizophrenia: a review of recent research and trends.

Authors:  Seth Kurzban; Lisa Davis; John S Brekke
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

3.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

Authors:  M Lambert; C Correll
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

Review 4.  The antecedents of schizophrenia: a review of birth cohort studies.

Authors:  Joy Welham; Matti Isohanni; Peter Jones; John McGrath
Journal:  Schizophr Bull       Date:  2008-07-24       Impact factor: 9.306

Review 5.  Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Authors:  Terry E Goldberg; Richard S E Keefe; Robert S Goldman; Delbert G Robinson; Philip D Harvey
Journal:  Neuropsychopharmacology       Date:  2010-01-20       Impact factor: 7.853

6.  Cognitive deficits in recent-onset and chronic schizophrenia.

Authors:  S R Sponheim; R E Jung; L J Seidman; R I Mesholam-Gately; D S Manoach; D S O'Leary; B C Ho; N C Andreasen; J Lauriello; S C Schulz
Journal:  J Psychiatr Res       Date:  2009-10-29       Impact factor: 4.791

Review 7.  Age of onset of schizophrenia: perspectives from structural neuroimaging studies.

Authors:  Nitin Gogtay; Nora S Vyas; Renee Testa; Stephen J Wood; Christos Pantelis
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

Review 8.  Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond.

Authors:  Emre Bora; Murat Yücel; Christos Pantelis
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

9.  Childhood determinants of adult psychiatric disorder.

Authors:  Tom Fryers; Traolach Brugha
Journal:  Clin Pract Epidemiol Ment Health       Date:  2013-02-22

10.  Neuropsychological impairments predict the clinical course in schizophrenia.

Authors:  Wolfgang Wölwer; Jürgen Brinkmeyer; Mathias Riesbeck; Lena Freimüller; Ansgar Klimke; Michael Wagner; Hans-Jürgen Möller; Stefan Klingberg; Wolfgang Gaebel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.